In comments submitted to the FDA, NPC outlined ways to improve how the exchange of clinical and economic information between biopharmaceutical manufacturers, payers, and population-health decision makers is regulated.

Health plans collect huge amounts of data through electronic health records, administrative claims, mobile health devices and other sources. This white paper explores whether the data simply sits on a shelf, or is used to shape care delivery, improve system efficiency, and achieve better health outcomes.

NPC President Dan Leonard recently sat down for a conversation with Julie Block, President and CEO of the National Eczema Association, to discuss atopic dermatitis (AD) and value assessment frameworks.